The University of Chicago Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to Salgia, Ravi
Item TypeName
Academic Article Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Academic Article Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Academic Article Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Academic Article EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Academic Article Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Academic Article Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Academic Article Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Academic Article Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Academic Article Temozolomide and/or Erlotinib in the Treatment of Lung Cancer Patients With Progressive Central Nervous System Metastases.
Academic Article Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
Academic Article Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.
Academic Article Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
Academic Article Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC).
Concept Erlotinib Hydrochloride
Search Criteria
  • Erlotinib Hydrochloride